Our top pick for
Recro Pharma, Inc is a drug manufacturers-specialty & generic business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars. Recro Pharma employs 185 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$1.49 - $9.19|
|50-day moving average||$3.21|
|200-day moving average||$2.92|
|Wall St. target price||$5.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.75|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Recro Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Recro Pharma shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $205,000.
The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$66.5 million|
|Gross profit TTM||$12.4 million|
|Return on assets TTM||-4.88%|
|Return on equity TTM||0%|
|Market capitalisation||$92.5 million|
TTM: trailing 12 months
There are currently 1.4 million Recro Pharma shares held short by investors – that's known as Recro Pharma's "short interest". This figure is 1.4% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Recro Pharma shares can be evaluated.
Recro Pharma's "short interest ratio" (SIR) is the quantity of Recro Pharma shares currently shorted divided by the average quantity of Recro Pharma shares traded daily (recently around 418083.87096774). Recro Pharma's SIR currently stands at 3.41. In other words for every 100,000 Recro Pharma shares traded daily on the market, roughly 3410 shares are currently held short.
However Recro Pharma's short interest can also be evaluated against the total number of Recro Pharma shares, or, against the total number of tradable Recro Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Recro Pharma's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Recro Pharma shares in existence, roughly 50 shares are currently held short) or 0.0514% of the tradable shares (for every 100,000 tradable Recro Pharma shares, roughly 51 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Recro Pharma.
Find out more about how you can short Recro Pharma stock.
We're not expecting Recro Pharma to pay a dividend over the next 12 months.
Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.
Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $1.49 up to $9.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1826. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Malvern, Pennsylvania.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.